Special Issue

Diagnostics and Vaccine Development for Emerging Infectious Diseases

Message from the Guest Editor

This Special Issue focuses on the design of diagnostics and vaccines for different types of emerging infectious diseases. Examples include HIV infection, filovirus diseases, flavivirus diseases, Nipah virus infection, and the coronaviruses. We need to continually develop better diagnostic tools that can provide early detection of pathogens, agents of infectious diseases. Second, given the diversity of these pathogens and the heterogeneity of ways in which the human immune system may be primed to control and provide protection, there is an urgent need to design and develop multiple different platforms for next-generation vaccines. It is very important that we identify precise and practical targets for designing effective diagnostics that can be quickly translated into development. In addition, increasing the availability of new vaccine design platforms such as mRNA and viral vector technologies as well as the progress in peptide-based multi-epitope vaccines, including in identifying precise and potent targets for the design of effective vaccines against emerging infectious diseases, is needed now more than ever. I look forward to receiving your contributions.

Guest Editor

Dr. Syed Faraz Ahmed

Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia

Deadline for manuscript submissions

closed (10 May 2023)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/132939

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

